Meta-Analysis
Copyright ©The Author(s) 2022.
World J Hepatol. Apr 27, 2022; 14(4): 827-845
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.827
Table 1 Main characteristics of the 22 included studies [34 subgroups; receiving bolus injection (n = 8) or continuous infusion (n = 26)]. Atrial natriuretic peptide was tested in 19 studies (215 patients), B-type natriuretic peptide in one study (7 patients), and urodilatin in two studies (21 patients)
Ref.CountryStudy typePatient nDrugComparatorAdmDose (ng/kg/min or ng/kg)Duration (min)Post-infusion follow-up (min)Age (mean)Male (%)Ascites severity: Mild/moderate/ severe/refractoryS- or P-sodium (mmol/L) mean ± SEQuality assessments (risk of bias)
NOS
RoB2
Abraham et al[31], 1995United StatesNon-random6ANPNoneCont15018018044.5676/0/0/0NRLow-
6ANPNoneCont15018018049.51001/3/2/0
Ando[32], 1991JapanNon-random10ANPNoneBolus1000NA9057.1800/5/5/0138.3 ± 0.7Low-
6ANPNoneBolus1000NA9058.7670/3/3/0134.2 ± 0.2
Badalamenti et al[33], 1992ItalyNon-random9ANPNoneBolus1000NA9057.8780/5/4/0134.7 ± 1.6Low-
4ANPNoneCont2060063.3750/3/1/0Moderate
Carstens et al[36], 1998DenmarkRCT15UrodilatinPlaceboCont20606050.66015/0/0/0137.0 ± 0.5-Low
Carstens et al[37], 2007DenmarkRCT6UrodilatinPlaceboCont20909054.0670/0/0/6133.3 ± 2.0-Low
Ferrier et al[14], 1989SwitzerlandNon-random7ANPNoneCont36606054.3570/7/0/0NRModerate-
Fried et al[34], 1990United States/SwitzerlandRCT11ANPPlaceboCont1512090NR8211/0/0/0NR-Moderate
RCT8ANPPlaceboCont3012090NR888/0/0/0
RCT9ANPPlaceboCont6012090NR899/0/0/0
Gerbes et al[35], 1988GermanyNon-random4ANPNoneCont503090NRNRNRNRModerate-
Ginès et al[22], 1992SpainNon-random5ANPNoneCont5060057.0600/5/0/0NRModerate-
11ANPNoneCont50600730/11/0/0
Heim et al[23], 1990GermanyNon-random8ANPNoneBolus500NA6054.5750/8/0/0NRLow-
Jespersen et al[12], 1995DenmarkNon-random9ANPNoneBolus2000NA12049.0890/7/2/0NRLow-
Laffi et al[15], 1989ItalyNon-random8ANPNoneBolus1000NA90056.4750/0/0/8131.8 ± 2.6Low-
Laffi et al[24], 1989ItalyNon-random5ANPNoneCont100457558.0600/5/0/0NRLow-
4ANPNoneCont100457556.4250/4/0/0
6ANPNoneCont100457554.0830/6/0/0
La Villa et al[16], 1995ItalyNon-random7BNPNoneCont13.861606056.0570/7/0/0135.0 ± 1.0Low-
Legault et al[25], 1993CanadaNon-random5ANPNoneCont15120120NR805/0/0/0139.0 ± 2.0Low-
7ANPNoneCont15120120NR717/0/0/0133.0 ± 1.0
Miyase et al[26], 1990JapanNon-random6ANPNoneBolus500NA9058.0NR6/0/0/0NRLow-
Morali et al[13], 1991CanadaNon-random5ANPNoneCont151206054.0805/0/0/0133.0 ± 1.0Low-
12ANPNoneCont151206053.0670/0/0/12138.0 ± 1.0
Morali et al[11], 1992CanadaNon-random6ANPNoneCont15120056.81000/0/0/6NRLow-
4ANPNoneCont15120064.31000/0/0/4
Salerno et al[27], 1988ItalyNon-random7ANPPlaceboBolus1000NA6056.61000/2/5/0NRLow-
Tobe et al[28], 1993CanadaNon-random8ANPNoneCont15120052.41008/0/0/0NRLow-
Tobe et al[29], 1993CanadaNon-random6ANPNoneCont15120058.0670/0/0/6NRLow-
Wong et al[30], 1993CanadaRCT3ANPAlbuminCont151206058.0673/0/0/0135.0 ± 5.0-Low
10ANPAlbuminCont151206054.0700/0/0/10134.0 ± 1.0